Cargando…

FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy

BACKGROUND: We studied whether maximum standardized uptake values (SUV) from [(18) F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC). METHODS: Eighty-four patients were treated prospectively with 74 Gy(RBE) proton therapy and con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Zuo-Lin, Erasmus, Jeremy, Komaki, Ritsuko, Cox, James D, Chang, Joe Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444399/ https://www.ncbi.nlm.nih.gov/pubmed/22929048 http://dx.doi.org/10.1186/1748-717X-7-144

Ejemplares similares

Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial
por: Zhu, Zhengfei, et al.
Publicado: (2014)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer
por: Zhu, Jun, et al.
Publicado: (2017)

Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
por: Doireau, V, et al.
Publicado: (1999)

Proton re-irradiation of unresectable recurrent head and neck cancers
por: Gordon, Konstantin, et al.
Publicado: (2021)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I‐II or unresected stage III pancreatic cancer
por: Ma, Sung J., et al.
Publicado: (2019)

Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer
por: Harada, Hideyuki, et al.
Publicado: (2016)

Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer
por: Zhang, Qin, et al.
Publicado: (2022)

Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer
por: Hitchcock, Kathryn E, et al.
Publicado: (2017)

Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
por: Chen, Liyao, et al.
Publicado: (2020)

Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer
por: Komaki, Ritsuko, et al.
Publicado: (2011)

Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021)

Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
por: Sakaguchi, Tadashi, et al.
Publicado: (2021)

Recurrent PET FDG Uptake after Sequential Chemotherapy and Radiation Therapy for DLBCL of the Tibia: A Case Report and Review of the Literature
por: Miles, Edward F., et al.
Publicado: (2011)

Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy
por: Rubie, H, et al.
Publicado: (2003)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]
por: Yokoyama, A., et al.
Publicado: (1998)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series
por: Dasari, Srikiran, et al.
Publicado: (2022)

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018)

Prediction of Recurrence by Preoperative Intratumoral FDG Uptake Heterogeneity in Endometrioid Endometrial Cancer
por: Kang, Seo Young, et al.
Publicado: (2017)

Long‐term outcomes of high‐dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall‐cell lung cancer
por: Ohnishi, Kayoko, et al.
Publicado: (2021)

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma
por: Kim, Young-Il, et al.
Publicado: (2013)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer
por: Donahue, Timothy R., et al.
Publicado: (2010)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Current status and future directions in unresectable stage III non-small cell lung cancer
por: Arellano, Esperanza Arriola, et al.
Publicado: (2020)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Staging recurrent ovarian cancer with (18)FDG PET/CT
por: DRAGOSAVAC, SANJA, et al.
Publicado: (2013)

Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer
por: Nakamura, Ikuo, et al.
Publicado: (2023)

Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer
por: Ma, Sung Jun, et al.
Publicado: (2018)

Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study
por: Clausen, Malene Martini, et al.
Publicado: (2014)

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
por: Aspinall, Sherrie L, et al.
Publicado: (2015)

Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer
por: Bang, Ji-In, et al.
Publicado: (2018)

Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
por: Thatcher, Nicholas, et al.
Publicado: (2010)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bm71ovapur81obc4mhs917j3ug